01/31/23 7:00 AMNasdaq : FWBI clinical triallow floatFirst Wave BioPharma Announces Initiation of Phase 2 Trial Investigating Enhanced Adrulipase Formulation in Exocrine Pancreatic Insufficiency in Patients with Cystic FibrosisFirst Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted,RHEA-AIneutral
01/30/23 7:00 AMNasdaq : FWBI conferenceslow floatFirst Wave BioPharma to Present at the BIO CEO & Investor ConferenceFirst Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announcedRHEA-AIneutral
01/25/23 7:00 AMNasdaq : FWBI low floatFirst Wave BioPharma Announces Expansion of Adrulipase Intellectual Property PortfolioFirst Wave BioPharma, Inc. (NASDAQ: FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announcedRHEA-AIneutral
01/24/23 7:00 AMNasdaq : FWBI conferenceslow floatFirst Wave BioPharma to Present at Sequire Biotechnology ConferenceFirst Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announcedRHEA-AIneutral
01/13/23 4:00 PMNasdaq : FWBI clinical triallow floatFirst Wave BioPharma Provides Update on IND Filing For Phase 2 Trial of Enhanced Microgranule Formulation of Adrulipase for Exocrine Pancreatic InsufficiencyFirst Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced thatRHEA-AIneutral
01/13/23 10:20 AMNasdaq : FWBI low floatFirst Wave BioPharma Announces Results of Special Meeting of StockholdersFirst Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, todayRHEA-AIneutral
01/09/23 9:10 AMNasdaq : FWBI low floatFirst Wave BioPharma Announces Adjournment of Special MeetingFirst Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, todayRHEA-AIneutral
01/05/23 9:45 AMNasdaq : FWBI, ZVSA managementlow floatZyVersa Therapeutics Appoints Three New Board MembersZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or "ZyVersa"), a clinical- stageRHEA-AIneutral
12/12/22 7:30 AMNasdaq : FWBI conferenceslow floatFirst Wave BioPharma to Participate in BIO Partnering @ JPM During “J.P. Morgan Week 2023”First Wave BioPharma, Inc. (NASDAQ: FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announcedRHEA-AIneutral
12/05/22 7:00 AMNasdaq : FWBI clinical triallow floatFirst Wave BioPharma Announces Initial Clinical Sites for its Phase 2 Trial of Enhanced Microgranule Delivery Formulation of AdrulipaseFirst Wave BioPharma, Inc. (NASDAQ: FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapiesRHEA-AIneutral